English
简体中文
Total: £ 56.28
Published Date: 2024-08-20 | Pages: 95 | Tables: 209 | Pharma & Healthcare
The global Gene Editing Drug market was valued at US$ 1259 million in 2023 and is anticipated to reach US$ 3305.4 million by 2030, witnessing a CAGR of 14.8% during the forecast period 2024-2030.
Gene editing drugs are an innovative biomedical treatment method that treat diseases by directly modifying a patient's genes. These drugs use various gene editing technologies, such as CRISPR-Cas9, ZFN (zinc finger nuclease), to precisely edit the patient's DNA sequence. Overall, the field of gene-editing drugs has great potential to treat a variety of diseases, but the field will continue to evolve and advance as ethical, safety, and legal issues are addressed.
This report aims to provide a comprehensive presentation of the global market for Gene Editing Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Editing Drug.
Report Scope
The Gene Editing Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gene Editing Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Editing Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Sangamo Therapeutics
Bluebird Bio
Beam Therapeutics
Yaotang Biotechnology
ICamuno Biotherapeutics
Reforgene Medicine
Star Eyed Creature
Segment by Type
CRISPR-Cas9 Gene Editing Drugs
Zinc Finger Nuclease Gene Editing Drugs
Others
Segment by Application
General Hospital
Specialty Hospital
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Gene Editing Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Gene Editing Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Gene Editing Drug Market Overview
1.1 Product Overview and Scope of Gene Editing Drug
1.2 Gene Editing Drug Segment by Type
1.2.1 Global Gene Editing Drug Market Value Comparison by Type (2024-2030)
1.2.2 CRISPR-Cas9 Gene Editing Drugs
1.2.3 Zinc Finger Nuclease Gene Editing Drugs
1.2.4 Others
1.3 Gene Editing Drug Segment by Application
1.3.1 Global Gene Editing Drug Market Value by Application: (2024-2030)
1.3.2 General Hospital
1.3.3 Specialty Hospital
1.4 Global Gene Editing Drug Market Size Estimates and Forecasts
1.4.1 Global Gene Editing Drug Revenue 2019-2030
1.4.2 Global Gene Editing Drug Sales 2019-2030
1.4.3 Global Gene Editing Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Gene Editing Drug Market Competition by Manufacturers
2.1 Global Gene Editing Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Gene Editing Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Gene Editing Drug Average Price by Manufacturers (2019-2024)
2.4 Global Gene Editing Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Gene Editing Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Gene Editing Drug, Product Type & Application
2.7 Gene Editing Drug Market Competitive Situation and Trends
2.7.1 Gene Editing Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Gene Editing Drug Players Market Share by Revenue
2.7.3 Global Gene Editing Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Gene Editing Drug Retrospective Market Scenario by Region
3.1 Global Gene Editing Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Gene Editing Drug Global Gene Editing Drug Sales by Region: 2019-2030
3.2.1 Global Gene Editing Drug Sales by Region: 2019-2024
3.2.2 Global Gene Editing Drug Sales by Region: 2025-2030
3.3 Global Gene Editing Drug Global Gene Editing Drug Revenue by Region: 2019-2030
3.3.1 Global Gene Editing Drug Revenue by Region: 2019-2024
3.3.2 Global Gene Editing Drug Revenue by Region: 2025-2030
3.4 North America Gene Editing Drug Market Facts & Figures by Country
3.4.1 North America Gene Editing Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Gene Editing Drug Sales by Country (2019-2030)
3.4.3 North America Gene Editing Drug Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Gene Editing Drug Market Facts & Figures by Country
3.5.1 Europe Gene Editing Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Gene Editing Drug Sales by Country (2019-2030)
3.5.3 Europe Gene Editing Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gene Editing Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Gene Editing Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Gene Editing Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Gene Editing Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Gene Editing Drug Market Facts & Figures by Country
3.7.1 Latin America Gene Editing Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Gene Editing Drug Sales by Country (2019-2030)
3.7.3 Latin America Gene Editing Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Gene Editing Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Gene Editing Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Gene Editing Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Gene Editing Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Gene Editing Drug Sales by Type (2019-2030)
4.1.1 Global Gene Editing Drug Sales by Type (2019-2024)
4.1.2 Global Gene Editing Drug Sales by Type (2025-2030)
4.1.3 Global Gene Editing Drug Sales Market Share by Type (2019-2030)
4.2 Global Gene Editing Drug Revenue by Type (2019-2030)
4.2.1 Global Gene Editing Drug Revenue by Type (2019-2024)
4.2.2 Global Gene Editing Drug Revenue by Type (2025-2030)
4.2.3 Global Gene Editing Drug Revenue Market Share by Type (2019-2030)
4.3 Global Gene Editing Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Gene Editing Drug Sales by Application (2019-2030)
5.1.1 Global Gene Editing Drug Sales by Application (2019-2024)
5.1.2 Global Gene Editing Drug Sales by Application (2025-2030)
5.1.3 Global Gene Editing Drug Sales Market Share by Application (2019-2030)
5.2 Global Gene Editing Drug Revenue by Application (2019-2030)
5.2.1 Global Gene Editing Drug Revenue by Application (2019-2024)
5.2.2 Global Gene Editing Drug Revenue by Application (2025-2030)
5.2.3 Global Gene Editing Drug Revenue Market Share by Application (2019-2030)
5.3 Global Gene Editing Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 CRISPR Therapeutics
6.1.1 CRISPR Therapeutics Corporation Information
6.1.2 CRISPR Therapeutics Description and Business Overview
6.1.3 CRISPR Therapeutics Gene Editing Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 CRISPR Therapeutics Gene Editing Drug Product Portfolio
6.1.5 CRISPR Therapeutics Recent Developments/Updates
6.2 Editas Medicine
6.2.1 Editas Medicine Corporation Information
6.2.2 Editas Medicine Description and Business Overview
6.2.3 Editas Medicine Gene Editing Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Editas Medicine Gene Editing Drug Product Portfolio
6.2.5 Editas Medicine Recent Developments/Updates
6.3 Intellia Therapeutics
6.3.1 Intellia Therapeutics Corporation Information
6.3.2 Intellia Therapeutics Description and Business Overview
6.3.3 Intellia Therapeutics Gene Editing Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Intellia Therapeutics Gene Editing Drug Product Portfolio
6.3.5 Intellia Therapeutics Recent Developments/Updates
6.4 Sangamo Therapeutics
6.4.1 Sangamo Therapeutics Corporation Information
6.4.2 Sangamo Therapeutics Description and Business Overview
6.4.3 Sangamo Therapeutics Gene Editing Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sangamo Therapeutics Gene Editing Drug Product Portfolio
6.4.5 Sangamo Therapeutics Recent Developments/Updates
6.5 Bluebird Bio
6.5.1 Bluebird Bio Corporation Information
6.5.2 Bluebird Bio Description and Business Overview
6.5.3 Bluebird Bio Gene Editing Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bluebird Bio Gene Editing Drug Product Portfolio
6.5.5 Bluebird Bio Recent Developments/Updates
6.6 Beam Therapeutics
6.6.1 Beam Therapeutics Corporation Information
6.6.2 Beam Therapeutics Description and Business Overview
6.6.3 Beam Therapeutics Gene Editing Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Beam Therapeutics Gene Editing Drug Product Portfolio
6.6.5 Beam Therapeutics Recent Developments/Updates
6.7 Yaotang Biotechnology
6.6.1 Yaotang Biotechnology Corporation Information
6.6.2 Yaotang Biotechnology Description and Business Overview
6.6.3 Yaotang Biotechnology Gene Editing Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Yaotang Biotechnology Gene Editing Drug Product Portfolio
6.7.5 Yaotang Biotechnology Recent Developments/Updates
6.8 ICamuno Biotherapeutics
6.8.1 ICamuno Biotherapeutics Corporation Information
6.8.2 ICamuno Biotherapeutics Description and Business Overview
6.8.3 ICamuno Biotherapeutics Gene Editing Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 ICamuno Biotherapeutics Gene Editing Drug Product Portfolio
6.8.5 ICamuno Biotherapeutics Recent Developments/Updates
6.9 Reforgene Medicine
6.9.1 Reforgene Medicine Corporation Information
6.9.2 Reforgene Medicine Description and Business Overview
6.9.3 Reforgene Medicine Gene Editing Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Reforgene Medicine Gene Editing Drug Product Portfolio
6.9.5 Reforgene Medicine Recent Developments/Updates
6.10 Star Eyed Creature
6.10.1 Star Eyed Creature Corporation Information
6.10.2 Star Eyed Creature Description and Business Overview
6.10.3 Star Eyed Creature Gene Editing Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Star Eyed Creature Gene Editing Drug Product Portfolio
6.10.5 Star Eyed Creature Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gene Editing Drug Industry Chain Analysis
7.2 Gene Editing Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gene Editing Drug Production Mode & Process
7.4 Gene Editing Drug Sales and Marketing
7.4.1 Gene Editing Drug Sales Channels
7.4.2 Gene Editing Drug Distributors
7.5 Gene Editing Drug Customers
8 Gene Editing Drug Market Dynamics
8.1 Gene Editing Drug Industry Trends
8.2 Gene Editing Drug Market Drivers
8.3 Gene Editing Drug Market Challenges
8.4 Gene Editing Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Gene Editing Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Gene Editing Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Gene Editing Drug Market Competitive Situation by Manufacturers in 2023
Table 4. Global Gene Editing Drug Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Gene Editing Drug Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Gene Editing Drug Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Gene Editing Drug Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Gene Editing Drug Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Gene Editing Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Gene Editing Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Gene Editing Drug, Product Type & Application
Table 12. Global Key Manufacturers of Gene Editing Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Gene Editing Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Editing Drug as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Gene Editing Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Gene Editing Drug Sales by Region (2019-2024) & (K Units)
Table 18. Global Gene Editing Drug Sales Market Share by Region (2019-2024)
Table 19. Global Gene Editing Drug Sales by Region (2025-2030) & (K Units)
Table 20. Global Gene Editing Drug Sales Market Share by Region (2025-2030)
Table 21. Global Gene Editing Drug Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Gene Editing Drug Revenue Market Share by Region (2019-2024)
Table 23. Global Gene Editing Drug Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Gene Editing Drug Revenue Market Share by Region (2025-2030)
Table 25. North America Gene Editing Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Gene Editing Drug Sales by Country (2019-2024) & (K Units)
Table 27. North America Gene Editing Drug Sales by Country (2025-2030) & (K Units)
Table 28. North America Gene Editing Drug Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Gene Editing Drug Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Gene Editing Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Gene Editing Drug Sales by Country (2019-2024) & (K Units)
Table 32. Europe Gene Editing Drug Sales by Country (2025-2030) & (K Units)
Table 33. Europe Gene Editing Drug Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Gene Editing Drug Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Gene Editing Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Gene Editing Drug Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Gene Editing Drug Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Gene Editing Drug Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Gene Editing Drug Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Gene Editing Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Gene Editing Drug Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Gene Editing Drug Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Gene Editing Drug Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Gene Editing Drug Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Gene Editing Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Gene Editing Drug Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Gene Editing Drug Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Gene Editing Drug Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Gene Editing Drug Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Gene Editing Drug Sales (K Units) by Type (2019-2024)
Table 51. Global Gene Editing Drug Sales (K Units) by Type (2025-2030)
Table 52. Global Gene Editing Drug Sales Market Share by Type (2019-2024)
Table 53. Global Gene Editing Drug Sales Market Share by Type (2025-2030)
Table 54. Global Gene Editing Drug Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Gene Editing Drug Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Gene Editing Drug Revenue Market Share by Type (2019-2024)
Table 57. Global Gene Editing Drug Revenue Market Share by Type (2025-2030)
Table 58. Global Gene Editing Drug Price (US$/Unit) by Type (2019-2024)
Table 59. Global Gene Editing Drug Price (US$/Unit) by Type (2025-2030)
Table 60. Global Gene Editing Drug Sales (K Units) by Application (2019-2024)
Table 61. Global Gene Editing Drug Sales (K Units) by Application (2025-2030)
Table 62. Global Gene Editing Drug Sales Market Share by Application (2019-2024)
Table 63. Global Gene Editing Drug Sales Market Share by Application (2025-2030)
Table 64. Global Gene Editing Drug Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Gene Editing Drug Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Gene Editing Drug Revenue Market Share by Application (2019-2024)
Table 67. Global Gene Editing Drug Revenue Market Share by Application (2025-2030)
Table 68. Global Gene Editing Drug Price (US$/Unit) by Application (2019-2024)
Table 69. Global Gene Editing Drug Price (US$/Unit) by Application (2025-2030)
Table 70. CRISPR Therapeutics Corporation Information
Table 71. CRISPR Therapeutics Description and Business Overview
Table 72. CRISPR Therapeutics Gene Editing Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. CRISPR Therapeutics Gene Editing Drug Product
Table 74. CRISPR Therapeutics Recent Developments/Updates
Table 75. Editas Medicine Corporation Information
Table 76. Editas Medicine Description and Business Overview
Table 77. Editas Medicine Gene Editing Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Editas Medicine Gene Editing Drug Product
Table 79. Editas Medicine Recent Developments/Updates
Table 80. Intellia Therapeutics Corporation Information
Table 81. Intellia Therapeutics Description and Business Overview
Table 82. Intellia Therapeutics Gene Editing Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Intellia Therapeutics Gene Editing Drug Product
Table 84. Intellia Therapeutics Recent Developments/Updates
Table 85. Sangamo Therapeutics Corporation Information
Table 86. Sangamo Therapeutics Description and Business Overview
Table 87. Sangamo Therapeutics Gene Editing Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Sangamo Therapeutics Gene Editing Drug Product
Table 89. Sangamo Therapeutics Recent Developments/Updates
Table 90. Bluebird Bio Corporation Information
Table 91. Bluebird Bio Description and Business Overview
Table 92. Bluebird Bio Gene Editing Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Bluebird Bio Gene Editing Drug Product
Table 94. Bluebird Bio Recent Developments/Updates
Table 95. Beam Therapeutics Corporation Information
Table 96. Beam Therapeutics Description and Business Overview
Table 97. Beam Therapeutics Gene Editing Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Beam Therapeutics Gene Editing Drug Product
Table 99. Beam Therapeutics Recent Developments/Updates
Table 100. Yaotang Biotechnology Corporation Information
Table 101. Yaotang Biotechnology Description and Business Overview
Table 102. Yaotang Biotechnology Gene Editing Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Yaotang Biotechnology Gene Editing Drug Product
Table 104. Yaotang Biotechnology Recent Developments/Updates
Table 105. ICamuno Biotherapeutics Corporation Information
Table 106. ICamuno Biotherapeutics Description and Business Overview
Table 107. ICamuno Biotherapeutics Gene Editing Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. ICamuno Biotherapeutics Gene Editing Drug Product
Table 109. ICamuno Biotherapeutics Recent Developments/Updates
Table 110. Reforgene Medicine Corporation Information
Table 111. Reforgene Medicine Description and Business Overview
Table 112. Reforgene Medicine Gene Editing Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Reforgene Medicine Gene Editing Drug Product
Table 114. Reforgene Medicine Recent Developments/Updates
Table 115. Star Eyed Creature Corporation Information
Table 116. Star Eyed Creature Description and Business Overview
Table 117. Star Eyed Creature Gene Editing Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Star Eyed Creature Gene Editing Drug Product
Table 119. Star Eyed Creature Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Gene Editing Drug Distributors List
Table 123. Gene Editing Drug Customers List
Table 124. Gene Editing Drug Market Trends
Table 125. Gene Editing Drug Market Drivers
Table 126. Gene Editing Drug Market Challenges
Table 127. Gene Editing Drug Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Gene Editing Drug
Figure 2. Global Gene Editing Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Gene Editing Drug Market Share by Type in 2023 & 2030
Figure 4. CRISPR-Cas9 Gene Editing Drugs Product Picture
Figure 5. Zinc Finger Nuclease Gene Editing Drugs Product Picture
Figure 6. Others Product Picture
Figure 7. Global Gene Editing Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Gene Editing Drug Market Share by Application in 2023 & 2030
Figure 9. General Hospital
Figure 10. Specialty Hospital
Figure 11. Global Gene Editing Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Gene Editing Drug Market Size (2019-2030) & (US$ Million)
Figure 13. Global Gene Editing Drug Sales (2019-2030) & (K Units)
Figure 14. Global Gene Editing Drug Average Price (US$/Unit) & (2019-2030)
Figure 15. Gene Editing Drug Report Years Considered
Figure 16. Gene Editing Drug Sales Share by Manufacturers in 2023
Figure 17. Global Gene Editing Drug Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Gene Editing Drug Players: Market Share by Revenue in 2023
Figure 19. Gene Editing Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Gene Editing Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Gene Editing Drug Sales Market Share by Country (2019-2030)
Figure 22. North America Gene Editing Drug Revenue Market Share by Country (2019-2030)
Figure 23. United States Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Gene Editing Drug Sales Market Share by Country (2019-2030)
Figure 26. Europe Gene Editing Drug Revenue Market Share by Country (2019-2030)
Figure 27. Germany Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Gene Editing Drug Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Gene Editing Drug Revenue Market Share by Region (2019-2030)
Figure 34. China Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Southeast Asia Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Latin America Gene Editing Drug Sales Market Share by Country (2019-2030)
Figure 42. Latin America Gene Editing Drug Revenue Market Share by Country (2019-2030)
Figure 43. Mexico Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Brazil Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Argentina Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Gene Editing Drug Sales Market Share by Country (2019-2030)
Figure 47. Middle East & Africa Gene Editing Drug Revenue Market Share by Country (2019-2030)
Figure 48. Turkey Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. UAE Gene Editing Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Global Sales Market Share of Gene Editing Drug by Type (2019-2030)
Figure 52. Global Revenue Market Share of Gene Editing Drug by Type (2019-2030)
Figure 53. Global Gene Editing Drug Price (US$/Unit) by Type (2019-2030)
Figure 54. Global Sales Market Share of Gene Editing Drug by Application (2019-2030)
Figure 55. Global Revenue Market Share of Gene Editing Drug by Application (2019-2030)
Figure 56. Global Gene Editing Drug Price (US$/Unit) by Application (2019-2030)
Figure 57. Gene Editing Drug Value Chain
Figure 58. Gene Editing Drug Production Process
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Distributors Profiles
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
